Key result
Immunosuppressive treatment for myocarditis significantly improved short-term left ventricular ejection fraction (difference 0.08; 95% CI 0.05-0.10) but did not affect death or heart transplantation.
Why the study?
Does immunosuppressive treatment improve left ventricular ejection fraction and clinical outcomes in patients with myocarditis?
Population
609 patients with myocarditis pooled from 9 articles
Comparison
Immunosuppressive treatment vs Conventional treatment
Design
Meta-analysis
Follow-up
short-term (≤3 months) and long-term
Authors
Loading...
May improve short-term LVEF in myocarditis without reducing death or transplantation; confirms surrogate benefit but leaves hard outcomes unresolved.
Meta-Analysis (n=609)
Does immunosuppressive treatment improve left ventricular ejection fraction and clinical outcomes in patients with myocarditis?
Mean Difference: 0.08 (95% CI 0.05–0.1)
Immunosuppressive treatment for myocarditis improves left ventricular systolic function and short-term remodeling, but does not significantly affect the rate of death or heart transplantation.
Lu et al. (2014) conducted a meta-analysis in myocarditis (n=609). Immunosuppressive treatment vs. Conventional treatment was evaluated on left ventricular ejection fraction at short-term (≤3 months) (difference 0.08, 95% CI 0.05-0.10). Immunosuppressive treatment for myocarditis significantly improved short-term left ventricular ejection fraction (difference 0.08; 95% CI 0.05-0.10) but did not affect death or heart transplantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: